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Abstract
A pre-requisite for bacterial pathogenesis is the successful interaction of a pathogen with a host. One mechanism used by a
broad range of Gram negative bacterial pathogens is to deliver effector proteins directly into host cells through a dedicated
type III secretion system where they modulate host cell function. The cycle inhibiting factor (Cif) family of effector proteins,
identified in a growing number of pathogens that harbour functional type III secretion systems and have a wide host range,
arrest the eukaryotic cell cycle. Here, the crystal structures of Cifs from the insect pathogen/nematode symbiont
Photorhabdus luminescens (a c-proteobacterium) and human pathogen Burkholderia pseudomallei (a b-proteobacterium) are
presented. Both of these proteins adopt an overall fold similar to the papain sub-family of cysteine proteases, as originally
identified in the structure of a truncated form of Cif from Enteropathogenic E. coli (EPEC), despite sharing only limited
sequence identity. The structure of an N-terminal region, referred to here as the ‘tail-domain’ (absent in the EPEC Cif
structure), suggests a surface likely to be involved in host-cell substrate recognition. The conformation of the Cys-His-Gln
catalytic triad is retained, and the essential cysteine is exposed to solvent and addressable by small molecule reagents.
These structures and biochemical work contribute to the rapidly expanding literature on Cifs, and direct further studies to
better understand the molecular details of the activity of these proteins.
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Introduction
Pathogenic bacteria can subvert host cell function by hijacking
vital cellular systems such as the cytoskeleton, vesicular trafficking,
apoptosis and the cell cycle [1,2,3]. In Gram-negative pathogens,
one route to communication with the host involves direct injection
of proteins known as ‘effectors’ from the bacterial to host cell
cytoplasm using a virulence-associated type III secretion system
(T3SS). Following translocation, these effectors function within the
host cell, remodelling cellular activities presumably to the benefit
of the pathogen.
The host cell cycle is one pathway being increasingly recognised
as a target for bacterial virulence mechanisms. Pathogen-derived
molecules that modulate the host cell cycle (which have been
termed ‘cyclomodulins’) stimulate diverse activities ranging from
promotion of cell growth through to altering differentiation and
inhibition of cell growth via blocking of the cell cycle. The first
T3SS-dependent cyclomodulin, known as cycle inhibiting factor
(Cif), was initially identified in enteropathogenic Escherichia coli
(EPEC) and enterohemorrhagic E. coli (EHEC) [4]. Using cultured
model host cells as a system for infection it was shown that EPEC-
Cif (CifEc) induces re-organisation of the actin cytoskeleton and
triggers cell cycle arrests at either the G2/M (with associated
doubling of DNA content) or G1/S phase transitions, in a T3SS-
dependent manner [4,5,6,7]. CifEc is necessary and sufficient for
this activity as an identical phenotype was observed in HeLa cells
following delivery of purified recombinant protein using the lipid-
based delivery system BioPORTER [4]. Cif-induced cell cycle
arrests at both the G1 and G2 stages are correlated with
accumulation of the cyclin-dependent kinase inhibitors (CKIs)
p21
waf1/cip1 and p27
kip1, which are known to be involved in cell
cycle progression [6].
Recently, homologues of Cif have been identified through
database searches of other Gram-negative bacteria that, as part of
their life-cycle, form pathogenic or symbiotic relationships with a
host; each also has at least one T3SS encoded in its genome [8].
These bacteria span different phylogentic classes and include
Burkholderia pseudomallei (b-proteobacteria), Yersinia pseudotuberculosis,
Photorhabdus luminescens and Photorhabdus asymbiotica (all c-proteo-
bacteria). B. pseudomallei is a pathogen of humans and an
established infection can cause melioidosis [9]. Infection with Y.
pseudotuberculosis, also a pathogen of humans, causes gastroenteritis
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luminescens is a symbiont for nematodes of the family Heterorhabdi-
tidae and a pathogen for a broad range of insects [11]. P. asymbiotica
is an emerging human pathogen [12]. Each of these Cif
homologues is capable of inducing cytopathic effects in HeLa
cells equivalent to those observed for CifEc [8]. Pair-wise
alignments with CifEc reveal 56%, 26%, 23% and 26% sequence
identity for Cifs from Y. pseudotuberculosis (CifYp), B. pseudomallei
(CifBp), P. luminescens (CifPl) and P. asymbiotica (CifPa) respectively [8]
(CifPl and CifBp share 36% identity, not counting a 35 amino acid
N-terminal extension in CifPl). Whilst the overall protein sequences
diverge significantly, the alignments also reveal strict conservation
of residues that comprise the catalytic triad (as identified in the
CifEc structure) and other residues that are likely important for
protein structure and function [8].
The crystal structure of a truncated form of CifEc (lacking the N-
terminal 99 amino acids) has recently been published [13]. Very
recently this has been followed by an independently determined
structure of CifBp [14]. These structures revealed the presence of a
conserved papain-like catalytic triad formed from residues Cys109,
His165 and Gln185 (CifEc numbering). The spatial arrangement
of these residues is very similar to that found in cysteine proteases,
and also certain acetyltranferases and transglutaminases. Mutation
of the residues that form this triad results in proteins no longer able
to induce cytopathic effects in model eukaryotic cells [8,13,14].
Details of how Cifs impact the host cell cycle at the molecular level
are yet to be determined, and are likely to remain elusive until host
cell targets and an observable activity are identified for these
proteins.
To further characterise this important family of bacterial
cyclomodulins, crystal structures of Cif from P. luminescens (CifPl),
and B. pseudomallei (CifBp, independent of that recently published),
have been determined. These proteins represent members of the
Cif family that are most divergent in sequence from CifEc. Like
CifEc, these proteins form monomer-dimer equilibria in solution,
as does P. asymbiotica Cif (CifPa). The active sites of CifPl and CifBp
are shown to contain reactive cysteines, which are accessible to
modification by a thiol-reactive compound. The crystal structures
of CifPl and CifBp both include regions towards the N-terminus of
the proteins, referred to as the ‘tail domain’, that were not present
in the truncated CifEc structure. These domains form an extended
surface adjacent to the active site suggestive of a binding interface
for interaction with a specific substrate. The positions of the
residues comprising the catalytic triad are well conserved, and
demonstrate that these proteins are structural as well as functional
homologues of CifEc.
Materials and Methods
Protein production
Genes encoding CifEc, CifBp, CifPl and CifPa were all cloned into
pET28a (Novagen) for overexpression as described elsewhere
[7,8], with the exception of CifBp which was initially cloned to
include the amino acid sequence as deposited in UNIPROT
(accession number: Q63KH5). The resulting plasmids were
transformed into either E. coli BL21(DE3) or B834(DE3) strains.
Bacterial cultures were grown in Luria-Bertani (LB) media
supplemented with kanamycin (50 mg/mL) at 37uC (with shaking)
to A600 between 0.4–0.6 prior to induction of expression with
1 mM isopropyl 1-thio-b-D-galactopyranoside (IPTG). Cultures of
B834(DE3) were also supplemented with 50 mg/L L-methionine.
Cells were grown for a further 2.5–4 hours before harvesting by
centrifugation. For initial preparation of CifBp, cell pellets were
resuspended in 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid (HEPES), 150 mM NaCl, 10 mM imidazole, pH 7.5
supplemented with 5 mM 4-(2-aminoethyl)-benzenesulfonyl fluo-
ride hydrochloride (AEBSF) and lysed by sonication. The lysate
was centrifuged and the supernatant applied to pre-equilibrated
5m L N i
2+-IMAC chelating columns (GE Healthcare). The
protein was eluted with an imidazole gradient (10–500 mM) over
15 column volumes. Fractions containing protein (as identified by
SDS-PAGE) were pooled and concentrated. The protein was then
injected onto a Hi-Load 16/60 Superdex 75 column (GE
Healthcare) pre-equilibrated with 20 mM trishydroxymethylami-
nomethane.HCl (Tris), 150 mM NaCl, pH 7.5. For all other
preparations (including a clone expressing CifBp starting from an
alternative start site, see below), cell pellets were re-suspended in
100 mM Tris, 500 mM NaCl, pH 8.2 and lysed using a Constant
Systems (UK) T-series high pressure cell disruptor. Clarified lysate
was applied to a pre-equilibrated (50 mM Tris, 500 mM NaCl,
5 mM imidazole, pH 8.0) 5 mL Ni
2+-IMAC chelating column,
eluted with a step to 250 mM imidazole in a 7.5 mL volume and
loaded on a Hi-Load 26/60 Superdex 75 column (GE Healthcare)
pre-equilibrated with 50 mM HEPES, 150 mM NaCl, pH 7.5.
Cif proteins elute as a mixture of monomeric and dimeric species
with the exception of CifBp that appears to run purely as a dimer.
Where possible, fractions containing monomer only were pooled,
exchanged by ultrafiltration into 20 mM HEPES, pH 7.5 and
concentrated to ,10 mg/mL for further study. Following
purification, analysis of CifPl by mass spectrometry (matrix-assisted
laser desorption/ionisation time of flight (MALDI-TOF)) revealed
the protein has a molecular weight of 29,475 Da (compared to
theoretical mass of ,37 kDa (including the vector-derived His-
Tag)), suggesting that the protein is cleaved in solution.
For production of selenomethionine-labelled CifPl (CifPl-SeMet)
the B834(DE3) E. coli strain harbouring the CifPl-pET28a plasmid
was grown initially in LB then diluted into minimal media
supplemented with L-methionine and kanamycin as above. At an
A600 of ,0.6, cells were gently pelleted and re-suspended in
minimal media (no methionine) and grown for 10 minutes.
60 mg/L solid L-selenomethionine was then added and the cells
grown for a further 20 minutes prior to induction of expression
with 1 mM IPTG; cell growth continued at 37uC overnight. CifPl-
SeMet was purified from cell culture as detailed for the native
protein.
Alkylation of reactive site cysteines
The haloalkylating reagent 6 - bromoacetyl - 2 - dimethylami-
nonaphthalene (badan) reacts with free thiols forming a stable
covalent thioether bond. The reaction generates a significant
increase in fluorescence intensity on binding. To determine
whether Cif proteins contain reactive thiol groups, CifPl and CifBp
were incubated with badan for 1 hour at pH 7.0. The change in
fluorescence intensity at 525 nm (excitation at 380 nm) over this
time was monitored. The intact mass of the resulting sample was
determined by matrix-assisted laser desorption/ionisation time of
flight (MALDI-TOF) mass spectrometry. Further, the sites of
modification in CifPl were mapped by tryptic peptide mass-
fingerprinting. MALDI-TOF and mass-fingerprinting analyses
were conducted by the Proteomics facility, JIC (Norwich).
Analytical gel filtration
A Superdex 10/30 GL S200 gel filtration column (GE
healthcare) equilibrated with 50 mM HEPES pH 7.2, 150 mM
NaCl was used for all analytical gel filtration experiments (flow
rate: 0.75 mL/min). Samples were prepared in 250 mL volumes
and loaded by syringe into a 100 mL loop before injection onto the
column.
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Crystals of CifPl were initially identified using the sitting drop
method of vapour diffusion at 20uC in plates set-up with a Douglas
Instruments OryxNano crystallization robot and commercially
available crystallization screens. The protein solution comprised
12 mg/mL CifPl in 20 mM HEPES, pH 7.5. Diffraction quality
crystals were grown in 100 mM tri-sodium citrate pH 6.2, 2.45 M
ammonium sulfate using 2 mL protein solution mixed with 2 mL
precipitant, again in sitting drops. Crystals of the selenomethio-
nine-labelled CifPl grew from the same conditions. Crystals grew
within three days.
Following analysis of the CifBp sequence (see Results) the protein
was subjected to a preparative-scale tryptic digest and re-purified
on a Hi-Load 16/60 Superdex 75 column, as above. Conditions
supporting growth of CifBp crystals from this sample were
identified using the hanging drop method of vapour diffusion at
20uC and commercially available crystallisation screens using this
protein (concentrated to 10 mg/mL). 1 mL protein solution was
mixed with 1 mL precipitant solution. After four months single
crystals grew from 10% PEG8000, 100 mM HEPES pH 7.5.
Data collection and structure determination
For data collection, crystals were cryo-protected in either N-
paratone oil (CifBp and CifPl-SeMet) or crystallisation buffer
containing 22% ethylene glycol (CifPl) prior to plunging into liquid
nitrogen. Diffraction data were collected at either the Daresbury-
SRS, station 9.6 (CifBp) or the Diamond Light Source, stations I03
(CifPl-SeMet) and I04 (CifPl). Crystals were maintained at
cryogenic temperatures during data collection. All data were
processed with MOSFLM [15] and scaled with SCALA [16] (as
implemented within the CCP4 suite [17]). 5% of the data were set
aside for the calculation of Rfree. A summary of data collection
parameters is given in Table 1. The structure of CifPl was solved
by the single wavelength anomalous dispersion (SAD) method,
using the selenomethionine labeled protein crystals. PHENIX.-
HYSS [18] located all five of the selenium atoms predicted to be in
the crystallized protein. These sites were used as input into
MLPHARE (as implemented in the CCP4 suite) to obtain initial
phases and Hendrickson-Lattman coefficients. Following density
modification with DM [19], Arp/Warp [20] was used to build an
initial model with ,150 of 253 residues automatically positioned.
This model was refined with REFMAC5 [21] and the resulting
maps inspected with COOT [22]. Following initial rebuilding
using the SeMet data, refinement was switched to minimize
against the isomorphous native dataset. Iterative cycles of
refinement and manual rebuilding (using REFMAC5 and COOT)
produced the final model which comprises residues Ser50 –
Leu302 of the native sequence, 1 sulphate, 1 glycerol and 198
water molecules. A summary of the refinement parameters is given
in Table 1.
The structure of CifBp was solved using the structure of CifPl as a
search model. Two molecules were placed in the asymmetric unit
by MOLREP. To minimize any bias in the electron density maps,
the starting model was converted to a poly-alanine trace and all
Table 1. Crystallographic data processing and refinement statistics.
CifPl - Native CifPl - SeMet CifBp
Data collection
Instrumentation DLS, station I03 DLS, station I04 Daresbury-SRS, station 9.6
Wavelength (A ˚) 0.972 0.972 0.92
Space Group P6122 P6122 P212121
Resolution range (A ˚)
a 41.9621.85 (1.9521.85) 41.8321.80 (1.9021.80) 22.0122.10 (2.2122.10)
Unit cell parameters (A ˚) a=b=59.13, c=293.17 a=b=58.91, c=292.38 a=54.9, b=77.7, c=115.0
Unique reflections
a, b, d 26,540 (3,343) 29,336 (4,159) 29,440 (4,223)
Multiplicity
a, b 12.0 (8.4) 10.8 (6.1) 5.0 (4.9)
Mean (I/s(I))
a, d 19.3 (4.4) 23.1 (5.2) 20.2 (3.5)
Completeness (%)
a, d 97.2 (88.1) 100.0 (100.0) 99.9 (99.9)
Rsym (%)
a, d 9.5 (38.7) 9.3 (44.6) 5.0 (37.4)
Refinement
Rcryst (%)
c 22.6 - 20.9
Rfree (%)
c 27.4 - 25.9
RmsBond (A ˚)
c 0.010 - 0.017
RmsAngles (u)
c 1.254 - 1.607
RmsChiral (u)
c 0.094 - 0.111
No. of non-hydrogen atoms 2,233 - 4,008
Cruickshank DPI (A ˚)
c 0.16 - 0.26
Ramachandran outliers 0 0
aFigures in parentheses represent the highest resolution shell.
bValues for multiplicity and completeness of the SeMet dataset are reported for separated anomalous pairs.
cRefinement statistics are as reported by REFMAC version 5.5.0066. RmsBond, RmsChiral and RmsAngle refer to the root-mean-square deviation from ‘ideal’ geometric
values described in the Refmac dictionary. Rfree=g(| |F|obs2|F|calc |)/g |F|obs - where |F|obs are observed structure factor amplitudes for a given reflection and |F|calc are
corresponding calculated structure factor amplitudes obtained from the refined model. Rfree uses only those reflections set aside as a ‘test set’. Rcryst is calculated as per
Rfree but using the ‘working set’ of reflections.
dReflection statistics are as reported by SCALA. Rsym is calculated as described in [16].
doi:10.1371/journal.pone.0005582.t001
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phase set using REFMAC without refinement. These phases were
then used in a density modification procedure involving solvent
flattening and two-fold NCS averaging (without recombining the
modified and starting phases) using DM. A new model was then
built into this ‘low-bias’ electron density map. Further refinement
and manual rebuilding (using REFMAC5 (with the NCS restraints
gradually loosened and eventually removed) and COOT)
produced the final model which comprises residues His14 –
Gly262 in chain A, His14 – Leu258 in chain B and 92 water
molecules.
For analysis, MOLPROBITY [23] and LSQMAN [24], were
used to generate Ramachandran plots and superimposed struc-
tures from which root-mean-square deviations (rmsds) based on Ca
atoms were determined. Protein structure figures have been
prepared with PYMOL (DeLano Scientific, USA). The coordi-
nates and structure factors for CifPl and CifBp have been deposited
with the Protein Data Bank with accession codes 3GQJ and
3GQM respectively.
Results
Protein production/characterisation
Sequences of the Cif homologues were analysed for regions of
disorder using RONN [25]. In CifEc, the only region of predicted
disorder (probability of disorder .50%) is localised to the N-
terminal 24 amino acids, which are known to encode the signal for
delivery into host cells by the EPEC T3SS machinery [26]. CifPl,
CifBp and CifYp display more extensive regions of disorder at their
N-terminus which includes the first 52, 63 and 47 residues
respectively. Only the first 26 amino acids of CifPa are predicted to
be disordered. CifPl is the only member of the family to display
disorder at the C-terminus; the last thirteen residues are predicted
to be unstructured.
Limited protelysis of CifBp with trypsin [27] identified a stable
fragment with a molecular weight of ,30 kDa, as determined
from SDS-PAGE gels (not shown). Following scale-up, this
fragment was re-purified as described above. MALDI-TOF
analysis of this CifBp fragment is most consistent with digestion
of the protein following Arg55 (PINNACLE Lab., Newcastle
University). As a Met residue was observed just downstream of this
region (Met61), the possibility that the start-site has been mis-
annotated in the sequence database was considered. Re-cloning
and functional characterisation of CifBp (using delivery of the
protein by both the infection model and the BioPORTER system)
demonstrates an activity equivalent to the original clone [8].
Therefore, CifBp may in fact start at Met61 and amino acid
numbering in this study reflects this (i.e. the sequence numbering
begins at M(1)ITPIISSNLG).
Following gel filtration, CifPl is observed to run at a lower
molecular mass than that predicted from the protein’s sequence.
MALDI-TOF analysis of purified CifPl is consistent with cleavage
after residue Lys48 of the full-length sequence (assuming no
cleavage at the C-terminus; Proteomics Facility, JIC, Norwich).
This removes the unstructured region from the N-terminus that
was identified bioinformatically, without the addition of exogenous
protease.
Cif proteins adopt monomer-dimer equilibria in solution
CifEc can be purified as a monomer or dimer in solution,
dependent on the concentration of NaCl [13]. Although it is
expected that Cif proteins function as monomers in vivo, each of
the Cifs produced in this study displays the properties of
monomer-dimer equilibria in solution, with the exception of CifBp
which purifies as a single species (whose apparent molecular
weight suggests a dimeric form).
Alkylation of Cys123 (CifPl) and Cys90 (CifBp)
The reactivity of the putative active site cysteines in CifPl and CifBp
was investigated by incubation of the proteins with the halo-alkylating
reagent badan. An increase in the fluorescence over time (at 525 nm,
not shown) was suggestive of alkylation events. CifPl and CifBp only
have one cysteine in the purified proteins (Cys123 and Cys90
respectively, CifPl has a second cysteine in its sequence (Cys20), but
this is lost following cleavage of the N-terminal unstructured region).
Comparison of the intact mass of the proteins pre- and post-
incubation with badan, as determined by MALDI-TOF mass
spectrometry, reveals an increase consistent with modification at a
single site in both proteins (covalent modification with a single badan
molecule would result in a increase of 211 Da). Mass fingerprinting
analysis of CifPl localises the site of modification to the cysteine-
containing peptide ‘IDESVSELGGLEMYQEMVGVNPYDP-
TEPVCGLSAQNIFK’, which shifts from 4261.5 Da (theoretical
mass of 4260.8 Da) to 4472.8 Da (theoretical mass 4471.7 Da), an
experimentally measured shift of 211.3 Da. To date, it has not been
possible to observe the cysteine-containing peptide in CifBp by
MALDI-TOF in either the native or modified form.
Overall structures of CifPl and CifBp
The structures of CifPl and CifBp closely resemble one another
and comprise a head-and-tail domain arrangement reminiscent of
a comma or apostrophe (Fig. 1). The structure of CifPl overlays on
CifBp with rmsds of 1.24 A ˚ (chain A, 226 equivalent Ca atoms) and
Figure 1. Molecular architecture of CifPl. (a) The overall structure
of CifPl resembles a ‘comma’ formed by the tail- and head-domains,
which are coloured blue and green respectively. The ‘occluding loop’ is
shown in violet, and the location of the proposed active site is marked
with a yellow sphere corresponding to the position of the thiol group of
Cys123. (b) Domain organisation of CifPl as described in the text,
coloured as above.
doi:10.1371/journal.pone.0005582.g001
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CifBp overlay with an rmsd of 0.42 A ˚ (245 equivalent Ca atoms)
and can therefore be considered essentially identical. The tail
regions of CifPl and CifBp are formed by the first 72 and 75
residues of the proteins visible in the structures and are equivalent
to a significant proportion of the protein removed in the truncated
CifEc structure. The head domains of CifPl and CifBp comprise the
C-terminal 60% and 67%, respectively (of the protein visible in the
structures), and this region is structurally conserved with CifEc.
CifPl and CifBp overlay on the structure of CifEc (chain A) with an
rmsd of 1.33 A ˚ and 1.20 A ˚ respectively (145 and 151 equivalent
Ca atoms). Therefore CifPl and CifBp, like CifEc, are structurally
related to members of the cysteine protease family and most
closely related to AvrPphB [28], a YopT-like effector protein from
the plant pathogen Pseudomonas syringae pv. phaseolicola. CifPl and
CifBp overlay on AvrPphB with an rmsd of 1.80 A ˚ and 1.76 A ˚
respectively (58 and 56 equivalent Ca atoms). The structure of
CifBp determined here is virtually identical to that recently
determined independently [14]. Based on structural homology,
Cifs are best classified as papain-like cysteine proteases, although
they have not yet been shown to possess protease activity.
The structure of the active site
A cysteine protease-like catalytic triad was initially identified in
the structure of CifEc and comprises residues Cys109, His165 and
Gln185. In CifPl the equivalent residues are Cys123, His181 and
Gln200; in CifBp they are Cys90, His145 and Gln165. The
cysteine of this triad is essential for the activity of Cifs as mutation
of this residue leads to loss of the cell cycle arrest phenotype in cell-
based assays [8,14]. The relative positions of the Cys-His-Gln
residues in each of the proteins are highly conserved, suggesting
these proteins perform the same catalytic function.
The structure of the active site triad of CifPl is shown in Fig. 2(a).
The active site cysteine is located at the N-terminus of 13 residue a-
helix (a5) with the side chains of His181 and Gln200 arising from
the b2 and b3-strands respectively. In both CifPl and CifBp, residues
of the catalytic triad are connected through hydrogen bond
interactions. The thiol group of the putative catalytic cysteine is
positioned 3.9 A ˚ from the N
d1 atom of His181 (CifPl numbering).
The orientation of His181 is stabilised by a hydrogen bond from the
N
e2 atom of this residue to the O
e1 atom of Gln200 (2.7 A ˚, CifPl
numbering). These inter-residue distances are similar to those found
in papain (which has a Cys-His-Asn triad [29]), and will presumably
enhance the nucleophilicity of the active site cysteine in Cifs in a
similar manner to that observed in this archetypal cysteine protease.
Also, the cysteine thiol group is likely affected by the close approach
of the NH groups of backbone amides from residues 124 and 182
(CifPl numbering). Further, as noted above, the cysteine residue
resides at the N-terminal end of an a-helix. The electrostatic
properties of helix macrodipoles have previously been implicated in
altering the reactivity (significantly reducing the pKa) of cysteine
residues positioned at the N-termini of a-helices [30].
A number of other residues, conserved across the Cif family, are
positioned near the putative active site. The side chain of Asp202
(CifPl numbering, see Fig. 2(a)) projects into a solvated pocket in
Cifs and could be involved in either modulating the electrostatic
properties of the active site or substrate binding. In either role, this
residue significantly contributes to the negative surface potential
observed at this site (see below). The side chains of Leu203 and
Asn175 (CifPl numbering) are prominently displayed on the
protein surface (see Fig. 2(a)) and are prime candidates for residues
that could make interactions with substrates. In addition, glycine
residues at positions 124 and 180 (CifPl numbering) may be
necessary to allow the close-approach of substrates to the active
centre. The backbone dihedral angles adopted by these residues
are not restricted to glycines, suggesting they are not conserved for
purely structural reasons.
The structure of the occluding loop identified in CifEc is
conserved in CifPl and CifBp
First observed in the structure of CifEc, the so-called ‘occluding
loop’, which spans residues 189–195 (CifEc numbering), lies
Figure 2. Features of the active site and tail domain of CifPl. (a) Active site of CifPl. Hydrogen bonds between residues of the proposed active
site triad (Cys123, His181, Gln200) are shown as dotted yellow lines. Residues Gly124, Asn175, Gly180, Asp202 and Leu203, which are fully conserved
in Cifs, are also shown. (b) Conserved-residues within the tail-domain. The locations of five residues within the tail-domain that are conserved among
all known Cifs are marked. The position of Leu203 and the Cys123 are also shown to aid orientation.
doi:10.1371/journal.pone.0005582.g002
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this loop appears to partially block the catalytic site, and may even
regulate access to the active centre via a gating mechanism [13].
The structures presented here show that the conformation of the
occluding loop is conserved in both CifPl (residues 203–212) and
CifBp (residues 168–177). Comparison of the B-factors of the
residues that comprise the occluding loop with those in the core of
the fold suggests the conformation of this region is quite rigid and
unlikely to be dynamic. This goes some way to arguing against a
role for this loop acting as a flexible gate regulating access to the
active site; an alternative role in supporting substrate specificity is
discussed below.
Structure of the tail-domain
As mentioned above, the published structure of CifEc is of a
truncated form, lacking the first 99 amino acids. The structures of
CifPl and CifBp presented here extend back to residues Ser50 (CifPl)
and His14 (CifBp). For CifBp, this directly follows the likely T3SS
signal, and it is perhaps not surprising that this is disordered in the
structure as it forms the recognition site for the T3SS and/or
associated chaperones. For CifPl, the N-terminal ,48 residues are
cleaved prior to crystallisation, therefore ,2 residues expected to
be in the crystallised protein but are not observed in the electron
density.
The overallstructure adoptedbythe tail-domainof CifPl is shown
in Fig. 2(b). It is formed from four a-helices (in the case of CifPl:
a1=residues 58–71; a2=72–79; a3=92–108 and a4=109–117)
and a ‘loop’ region that connects a4 to the catalytic cysteine residue
at the N-terminus of a5. Structural similarity searches with DALI
[31] do not reveal any other proteins (of known structure) that
encompass such a domain; this may therefore be unique to Cifs.
The region from a2 to the active site cysteine forms a prominent
surface immediately adjacent to the active site (see Fig. 2(b) and 3)
that may be important in determining the substrate specificity for
this enzyme. Indeed, mutations within this region in Cifs leads to
loss of function in cell-based assays (Oswald, unpublished results,
[14]). The tail-domain of CifBp (back to residue 14) adopts a
conformation very similar to that found in CifPl, even though there
is very little sequence identity between these proteins in this region.
Surface electrostatics near the active site of CifPl and CifBp
Electrostatic surface representations of CifPl and CifBp are
shown in Fig. 3. The most striking feature is how similar both the
overall shape and electrostatic potential of CifPl and CifBp are,
especially close to the active site and within the tail domain. Both
proteins contain a patch of positive charge immediately adjacent
to the catalytic cysteine and this area may interact with a
complementary charged surface on the substrate. Also close to the
cysteine is a small cavity displaying negative surface charge. As
mentioned above, the largest contributor to the negative surface of
this cavity is the side chain of Asp202 (CifPl numbering); a similar
pocket has been previously noted in CifBp [14]. The presence of a
neutral groove in the surface is also observed that may have a role
in substrate specificity.
Conserved residues map to the protein surface
A plot of the surface of CifPl coloured according to sequence
conservation across the protein family reveals conserved, surface
accessible residues cluster in two locations (Fig. 4(a)). The first of
these includes the active site and surrounds. Potential roles for
residues Gly124, Asn175, Gly180, Asp202 and Leu203 have been
described above. Asp76 and Ile94 reside within the tail domain.
Figure 3. Electrostatic potential surfaces of Cif proteins. (a) CifPl (b) CifBp. Solvent-accessible surfaces were calculated with a 1.2 A ˚ solvent
probe radius. Surface colourings are contoured over the same range for each structure (290 to +90 kbT/ec). The location of the catalytic cysteine
residue is shown by the yellow sphere.
doi:10.1371/journal.pone.0005582.g003
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hydrophobic core of the tail domain and likely stabilises its
structure. Asp76 is prominently displayed projecting towards the
catalytic site. As the side chain has no obvious role in maintaining
the architecture of the protein fold, this residue may be involved in
interacting with substrate. The second location includes residues
Glu159, Glu280 and Asp282. This region is distant from the active
site, and the role of this conserved surface patch is not immediately
apparent.
Discussion
Gram negative bacterial pathogens harbouring a virulence
associated type III secretion system (T3SS) are able to directly
inject effector proteins into host cells to modulate their activity,
presumably to the benefit of the pathogen. One family of T3S
effectors, the Cifs, re-program the host cell cycle causing arrest at
the G2/M or the G1/S transition. Significant advances in
understanding the molecular basis of Cif activity have recently
been made with the demonstration of conserved activity in cell-
based assays for all known Cif family members and structural
studies.
In this study the crystal structures of Cif from P. luminescences
(CifPl) and B. pseudomallei (CifBp) are presented. The structures
reveal a head-and-tail domain arrangement, with the head-
domain adopting an overall fold similar to papain-like cysteine
proteases. The structure of the tail-domain of CifPl and CifBp
presents an extensive surface area adjacent to the active site
suggestive of a binding surface for interaction with a specific
substrate (see Fig. 2(b), 3 and 4). Despite recent advances in the
studies of Cifs, the specific activity encoded within the proteins
(e.g. protease/acetyltransferase) and the specific host cell target/s
remain to be determined. This has, perhaps, been more
challenging than expected and one explanation for this is that
Cifs may be highly specific for their in vivo substrate. Due to its
position near the active site, a significant contribution to this
specificity will likely be conferred by the tail-domain, but will not
be limited to this. As mentioned above, it has been suggested that
the presence of an occluding loop in Cifs may restrict access to the
active site cysteine residue. However, incubation of CifPl and CifBp
with the halo-alkylating reagent badan reveals this residue in CifPl
and CifBp is addressable in solution. A similar result has also
recently been observed for CifEc and CifBp using the protease
inhibitor E-64 (trans-epoxysuccinyl-L-leucylamido(4-guanidino)bu-
tane) [14]. In the structures of CifPl and CifBp, 24.0% and 25.7%
of the surface area of the cysteine sulphur atoms respectively are
exposed to solvent (28.1 A ˚ 2 and 30.1 A ˚ 2, calculated using
AREAIMOL (as implemented in CCP4 [17]) with a 1.2 A ˚ probe
radius). Although badan is only a small molecule, not another
protein (the likely host cell target of Cifs), this shows that no
accessory factors are required to enable access to the cysteine from
solution. Therefore, rather than blocking access to the active site,
the occluding loop may be involved in binding substrate/
determining substrate specificity.
A set of 31 amino acid residues are fully conserved in all five Cif
sequences known to date (see Fig. 4(b) and S1). 27 of these were
present in the truncated CifEc structure and these largely cluster at
three locations: (1) the active site and surrounding region, (2) a
region that may be important for maintaining structural integrity
and (3) a region for which sequence/structural conservation was
not immediately apparent from the CifEc structure [8]. The
structures of CifPl and CifBp presented here show that the overall
position of these 27 residues are spatially conserved in Cifs.
Residues clustering in the active site region (Pro121, Gly124,
Figure 4. Conserved residues mapped to the surface of Cif. (a) Surface representation of CifPl showing locations of solvent-accessible
conserved residues. Green are non-conserved, white are semi-conserved and blue are absolutely conserved among all Cif homologues. Residues
located on the same face as the active site cysteine are labelled in black, grey labels denote conserved residues that are distant from the active site.
(b) Amino acid sequence of CifPl. Residues that are conserved between all known Cif homologues are marked in blue and underlined. Secondary
structure elements are given immediately above the sequence; oblongs and arrows indicate helices and sheets, while a solid line denotes ordered
loops. Secondary structure elements are coloured according to the domain structure in Fig. 1. The dashed lines at the N- and C-termini represent
regions that are not observed in the crystal structure. Stars indicate residues of the putative active site triad. A sequence alignment for all known Cifs
is given in Fig. S1.
doi:10.1371/journal.pone.0005582.g004
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Asp215-Trp216 (CifPl numbering)) are expected to be either
essential for maintaining the relative positions of the triad residues
or be involved in substrate binding. A role for the second region
(including residues Asp186, Asp188 and Glu280-Asp282 (all CifPl
numbering)) in maintaining a side-chain mediated inter-strand
hydrogen bond has been suggested [8]; this region also contains
residues that comprise the second conserved surface patch
(Fig. 4(a)), as mentioned above. A function for the third region
(residues Lys132, Leu133 and Asn289, CifPl numbering) is,
however, revealed in the structures of CifPl and CifBp. In these
structures these residues contribute to a surface that the loop
between a2 and a3 (part of the tail-domain) engages with.
Variation at these positions would destabilise the docking of this
region onto the rest of the structure.
The structures of CifPl and CifBp also present an opportunity to
put the remaining four conserved residues into a structural
context: Asn70, Asp76, Ile94 and Gly103 (CifPl numbering,
Asn36/Asp42/Ile60/Gly69 in CifBp and Asn52/Asp58/Ile76/
Gly88 in CifEc). Firstly, the O
d1 atom of Asn70/36 forms a
hydrogen bond to the backbone nitrogen of Pro118/Leu85 (CifPl/
CifBp numbering respectively), anchoring the loop between a4 and
a5 (which contains the active site cysteine residue at its N-
terminus). A stable, conserved structure in this region will be
crucial for the integrity of the catalytic centre and, likely, for
recruiting substrate. Putative roles for Asp76/42 and Ile94/60
have been described in the Results section. Gly103/69 resides
within a tight turn between a3 and a4 (see Fig. 2(b)), and the
importance of this residue is likely to be structural.
While Cif proteins are expected to function as monomers in vivo,
all Cifs recombinantly expressed to date form either monomer-
dimer equilibria in solution or are predominantly dimeric, as
revealed by gel filtration. However, crystal packing in the
structures of CifPl and CifBp are not consistent with a conserved
oligomeric state across the protein family, and any significance of
the dimeric forms observed in solution is not immediately
apparent. Interestingly, a dimeric state was also observed in the
structure of the truncated CifEc [13]. The structures of CifPl and
CifBp presented here show that this ‘helix-swapped’ dimer cannot
be consistent with the dimer formed in solution by the full-length
proteins as the tail-domain will fill the space occupied by the C-
terminal helix from the second molecule in this structure.
When delivered to cultured model host cells by an active T3SS,
or via BioPORTER, Cif proteins induce the same phenotype,
suggesting they recognise and act on a common substrate. For this
to be the case, the surface properties in the region of the active site
should be similar. Analysis of the electrostatic surface of CifPl and
CifBp (Fig. 3) and the localisation of conserved residues (labelled
black in Fig. 4(a)) in this region is supportive of this conclusion.
Further analysis of any specific interaction now requires
identification of the in vivo substrate of Cifs, and the role of these
conserved residues will be the subject of future work.
In summary, this manuscript describes the structures of CifPl
and CifBp, building on previous structural and functional studies of
this family of bacterial proteins that arrest the eukaryotic cell cycle.
While the specific substrate upon which these proteins act is yet to
be determined, these structures identify intriguing putative
interacting surfaces whose function can be investigated by
mutagenesis. The papain-like fold and putative catalytic triad
originally identified in the structure of CifEc are well conserved in
CifPl and CifBp, suggesting a conserved function for the protein
family.
Supporting Information
Figure S1 Alignment of known Cif sequences.
Found at: doi:10.1371/journal.pone.0005582.s001 (0.02 MB TIF)
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